Daniel Sharp

Daniel Sharp

Director/Board Member at ALCIDION GROUP LIMITED

Net worth: 157 832 $ as of 30/05/2026

Health Technology
Finance
Consumer Services

Profile

Mr. Daniel Sharp, CFA, is an Independent Non-Executive Director at Alcidion Group Ltd. He is on the Board of Directors at Botanix Pharmaceuticals Ltd. and Alcidion Group Ltd. Mr. Sharp was previously employed as an Independent Non-ExecutiveDirector by ImpediMed Ltd., an Independent Non-Executive Director by Race Oncology Ltd., an Executive Director by Canaccord Genuity (Australia) Ltd., and an Executive Director by Shaw & Partners Corporate Finance Pty Ltd. He received his undergraduate degree from Monash University and a graduate degree from Monash University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
29/06/2025 1,378,572 ( 0.1% ) 106 633 $ 30/05/2026
19/04/2026 2,964,646 ( 0.11% ) 51 199 $ 30/05/2026

Daniel Sharp active positions

CompaniesPositionStart
ALCIDION GROUP LIMITED Director/Board Member 31/08/2021
BOTANIX PHARMACEUTICALS LIMITED Director/Board Member 21/03/2022

Former positions of Daniel Sharp

CompaniesPositionEnd
IMPEDIMED LIMITED Director/Board Member 27/09/2023
RACURA ONCOLOGY LTD Director/Board Member 28/06/2023
Director/Board Member 31/12/2019
Corporate Officer/Principal -
See the detail of Daniel Sharp's experience

Training of Daniel Sharp

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

28

1st degree connections

7

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies7

Health Technology

Consumer Services

Health Technology

Finance

Technology Services

Finance

Health Technology